Again, the result holds for all M3 Pro models. The Apple M3 Pro 11-Core even takes the lead in terms of efficiency in some of the benchmarks. The text makes multiple direct comparisons between M3 Pro and M4 Pro efficiency.
It looks like they don't have benchmark results for Cinebench 2024 for some older models, so they're only shown when you switch to Cinebench R23. The Witcher 3 benchmark, for example, does show M3 Pro numbers by default.
You can add other M3 models for some of the efficiency benchmarks. The headline still holds true when comparing to M3 Pro models (though the exact efficiency diff depends quite a bit on the exact M3 Pro model/core count).
I'm perfectly happy with the performance of my iPhone SE (2020), and it's still receiving software updates, but the battery is severely degraded. The same was true for my first-generation iPhone SE; I was able to get a cheap replacement back then due to Apple's battery replacement program related to batterygate.
Access to cheap replacement batteries would definitely have an impact when deciding whether I should replace my phone or not. I believe Apple even mentioned the battery replacement program being a factor contributing to lower-than-expected sales a few years ago (sorry, can't find the source).
It's very common for discussions on this topic to only look at one particular factor and use it to fit some narrative one believes to be correct. Mentioning the difference in population age while ignoring things like population density or different climates is a good example of this.
They put a lot of money into long-term bonds before the latest interest rate hikes. These bonds now sell at a discount, so they can no longer cover all deposits by selling them.
Inactivated COVID-19 vaccines (that is, vaccines using virus copies that have been killed - live vaccines would be ones where the virus has been weakened) have been a thing for some time. IIRC China used a lot of them.
My understanding is that they're not quite as good as mRNA in terms of efficacy (though I haven't looked this up in some time.)
> Also, Hep C, HIV and herpes have no vaccine, so unclear what your statement is referring to anyway?
OP is talking about more vaccines as possible future mitigations - more vaccines as in new vaccines, not more vaccinations using existing ones (though that wouldn't hurt either.)
> It would typically happen maybe once a month at most, but it was almost always on a Sunday.
Do you recall if you slept in on those days? I tend to get a specific kind of headache if I sleep for too long.
This also happens if I take a nap during the day. I don't really take any naps because of that, but I remember hating being forced to nap in Kindergarten (at least during the first two years or so), probably for the same reason.
> Participants washed their gloved hands with a suspension of MS2 bacteriophage and hands were dried with one of the three hand-drying devices. [...] Over a height range of 0·15–1·65 m, the JAD [jet air dryer] dispersed an average of >60 and >1300-fold more plaque-forming units (PFU) compared to the WAD [warm air dryer] and PT [paper towels] (P < 0·0001), respectively.[1]
Okay, but I'm sure just-washed hands aren't all that dirty, right?
> This observational study was conducted to evaluate [...] hand hygiene practices among college students. [...] Overall, 72.9% of students washed their hands, 58.3% practiced hand hygiene (using either soap or hand sanitizer), and 26.1% washed their hands adequately.[2]
I couldn't find any epidemiological studies, but this feels like good enough of a reason to stick to other options considering these things are a solution in search of a problem anyway.
That's correct. Sberbank Europe is registered as an Austrian bank, so the Austrian equivalent of the FDIC has to cover deposits of up to 100K per client.
There's no mention of encryption at rest using your own key. To quote the ruling:
> If the second respondent (Google) subsequently refers to encryption technologies - such as the encryption of "data at rest" in the data centers - he must again be countered with recommendations 01/2020 of the EDSA. Namely, it states that a data importer (such as the Second Respondent) who is subject to 50 US Code § 1881a (“FISA 702”) has a direct obligation with regard to the imported data that is in his possession, custody or control to grant access to or release them. This obligation can expressly also apply to the cryptographic key without which the data cannot be read (ibid. margin no. 76).
> As long as the second respondent has the opportunity to access data in the Plain text access, the technical measures taken cannot be regarded as effective in the sense of the above considerations.
The last paragraph suggests true end-to-end encryption may be acceptable, but that's not how Google Analytics works.
I've had this issue before - some combination of relaunching System Preferences, toggling the "iCloud Mail" checkbox and smashing "OK" repeatedly eventually made it work.
My understanding is that existing inactivated (whole-virus) vaccines perform worse than mRNA-based spike-targeting vaccines when it comes to neutralization. Here's a small study comparing BNT162b2 and Coronavac[1].
There are plenty of countries where the vaccination rate is too low to effectively prevent the healthcare system from being overrun. In Austria, we were in another lockdown due to this just a month ago, with a vaccination rate of about 70% at the time (IIRC). This is in a country with a relatively high number of unoccupied ICU beds, and we still peaked at a level just short of where doctors would have to triage patients (and well where the quality of care could be kept at its usual level due to i.e. fewer nurses and doctors per patient.)
So no, the unvaccinated aren't solely at risk personally, they could also prevent vaccinated people from getting treated at the standard of care that they would normally expect. I'm not okay with that, so mandatory vaccination with fines for non-compliance seems like the lesser evil to me.
This study[1] shows 70% effectiveness against hospitalization for the Pfizer vaccine (based on a two-dose regime; the level of protection would likely be significantly higher for boosted populations).
I'll leave it to you to do the math on what this would mean for the healthcare system if we take current daily infections and remove that effect.
Public health authorities regularly perform that kind of risk-benefit analysis. Here's one by the FDA looking at the 5-11 age group: https://www.fda.gov/media/153507/download
My understanding is that this analysis assumed the observed myocarditis risk of the 12-15 age group would also apply here, but IIRC more recent data shows no myocarditis cases at all for the younger group.
There's a theory that links the occurrence of myocarditis to high testosterone levels, but that hasn't been proven yet. Existing data shows that the increased myocarditis risk (more or less) only applies to boys/young males.
Do we know how large this effect is for the unvaccinated? I'm still not sure if the numbers we're seeing from countries with relatively high seroprevalence through either vaccination, infection, or both can easily be applied to other countries.
This UK report[1] does show a corrected Hazard Ratio of 0.76 relative to Delta, but more than half of this group seems to have had a previous infection. Not sure what it would look like if you exclude them.
1:100000 was in reference to the "males < 40" age bucket in the UK study linked by OP. The myocarditis risk from infection for the 12-17 age group appears to be significantly higher according to this study[1] (1:1141), which gets us quite close to the Hong Kong study incidence if we assume two shots after the first dose.
> In any case, the risks are not directly comparable unless you assume 100% PCR-confirmed infection risk over six months, which is of course unrealistic.
I do wonder how unrealistic it is with Omicron, but maybe we'll get lucky and Omicron's less likely to cause myocarditis.